Altimmune Stock Price, News & Analysis

Altimmune, Inc. (Nasdaq: ALT) will report its fourth quarter and full year 2021 financial results on March 15, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), being developed for obesity and NASH. Additional developments include HepTcell™, an immunotherapeutic for chronic hepatitis B.

Altimmune, a clinical-stage biopharmaceutical company, has received FDA clearance for its IND application for the pemvidutide Phase 2 clinical trial targeting obesity. The trial is set to begin in Q1 2022, enrolling around 320 participants. Pemvidutide aims to treat obesity and has previously shown promising results, with a 10.3% average weight loss in a Phase 1 study. This trial will evaluate multiple dosages over 48 weeks, focusing on weight change and metabolic health. The company also develops treatments for non-alcoholic steatohepatitis (NASH).

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris, Chief Medical Officer, will present on pemvidutide, a dual receptor agonist targeting obesity and non-alcoholic steatohepatitis (NASH). The presentations will occur at the NASH-TAG Conference from January 6-8, 2022, in Park City, Utah. Dr. Harris will deliver an oral presentation on a placebo-controlled study of pemvidutide on January 8, 2022, at 8:10 am Mountain Time. The presentation details will be available on Altimmune's website post-conference, emphasizing the company's focus on innovative treatments for obesity and liver diseases.

Altimmune, Inc. (Nasdaq: ALT) announced the recruitment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. The Compensation Committee granted him equity awards under its 2018 Inducement Grant Plan, which includes options for 150,000 shares and 50,000 restricted stock units (RSUs). The exercise price for options will match the stock's closing price on the Grant Date. Vesting for these awards is contingent upon Mr. Eisenstadt’s continued employment, with full vesting occurring over four years.

Altimmune, Inc. (Nasdaq: ALT) announced the appointment of Richard Eisenstadt as Chief Financial Officer effective December 31, 2021, succeeding Will Brown. Eisenstadt brings over 30 years of experience in healthcare, demonstrating his capacity for managing drug development and commercial operations. He previously served as CFO at Aytu BioPharma and Neos Therapeutics, where he raised over $340 million. The leadership change comes as Altimmune aims to advance its clinical pipeline, including pemvidutide for obesity and HepTcell for chronic hepatitis B.

Altimmune, Inc. (Nasdaq: ALT) announced its management team's participation in several upcoming virtual conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will take place from November 29 to December 2, 2021. The 5th Annual NASH Summit 2021 is scheduled for November 30, 2021, at 9:00 am Eastern Time. Lastly, Altimmune will present at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021, at 10:55 am Eastern Time. Presentation materials and webcasts are accessible on their website.

On November 10, 2021, Altimmune, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker ALT, announced upcoming presentations by its management team at two significant investor conferences.

• Stifel’s 2021 Virtual Healthcare Conference: November 15, 2021, at 10:40 am Eastern Time.
• Jefferies London Healthcare Conference: November 18, 2021, at 8:00 am GMT.

Both sessions will be accessible via the Altimmune website.

Altimmune, Inc. (Nasdaq: ALT) reported significant advancements in its pemvidutide program, showcasing a reduction of liver fat to undetectable levels in subjects with hepatic steatosis following a 6-week treatment. The company ended Q3 2021 with approximately $200 million in cash and short-term investments.

Financially, Altimmune's Q3 revenue was $0.2 million, down from $2.9 million in Q3 2020, with a net loss of $33.5 million. The firm is advancing its obesity program and is set to initiate Phase 2 trials in 2022.

Altimmune, Inc. (Nasdaq: ALT) has announced that it will report its third quarter 2021 financial results on November 10, 2021. The management team will host a conference call at 8:30 am E.T. to discuss these results and provide a business update. Investors can participate via domestic and international dial-in numbers or join a webcast available through their official site.

Altimmune focuses on developing treatments for obesity and liver diseases, with ongoing projects like ALT-801 for NASH and HepTcell™ for chronic hepatitis B.